Paper16580903
Comparison of midazolam and simvastatin as cytochrome P450 3A probes.
Chung E and 3 others. Clin Pharmacol Ther, 2006. Cited by 91 papers, by iCite.
Cite this record
ConductScience Library. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Papers, record 16580903. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16580903
- Disease
- adrenal cortex carcinoma46 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Connected records2
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anesthetics, Intravenous | Major topic |
| Anticholesteremic Agents | Major topic |
| Cytochrome P-450 CYP3A | Major topic |
| Midazolam | Major topic |
| Simvastatin | Major topic |
| Administration, Oral | |
| Adult | |
| Area Under Curve | |
| Cross-Over Studies | |
| Female | |
| Humans | |
| Male |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03145285 | Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma | Results |
Source ClinicalTrials.gov
Cited by38
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 91 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42717157 | Verification of a Physiologically-based Pharmacokinetic Model for Predicting CYP3A4-mediated Simvastatin and Simvastatin Acid Drug-drug Interactions. | AAPS J | 2026 | https://conductscience.org/library/papers/42717157 | PubMed |
| 41350955 | Utilizing Physiologically Based Pharmacokinetic Modeling and Virtual Simulation for Simvastatin Tablets to Evaluate the Sensitivity of Using Parent vs Metabolite as Analyte on Bioequivalence Assessment. | AAPS J | 2025 | https://conductscience.org/library/papers/41350955 | PubMed |
| 38840420 | Clinically important pharmacokinetic drug-drug interactions with antibacterial agents. | Rev Esp Quimioter | 2024 | https://conductscience.org/library/papers/38840420 | PubMed |
| 38689161 | The Use of Microdosing for In vivo Phenotyping of Cytochrome P450 Enzymes: Where Do We Stand? A Narrative Review. | Eur J Drug Metab Pharmacokinet | 2024 | https://conductscience.org/library/papers/38689161 | PubMed |
| 37162619 | Intraindividual Variability in Absolute Bioavailability and Clearance of Midazolam in Healthy Individuals. | Clin Pharmacokinet | 2023 | https://conductscience.org/library/papers/37162619 | PubMed |
| 34783193 | Physiologically-based pharmacokinetic modeling to predict CYP3A4-mediated drug-drug interactions of finerenone. | CPT Pharmacometrics Syst Pharmacol | 2022 | https://conductscience.org/library/papers/34783193 | PubMed |
| 34519068 | Evaluation of the drug-drug interaction potential of treosulfan using a physiologically-based pharmacokinetic modelling approach. | Br J Clin Pharmacol | 2022 | https://conductscience.org/library/papers/34519068 | PubMed |
| 34228545 | Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile. | Antimicrob Agents Chemother | 2021 | https://conductscience.org/library/papers/34228545 | PubMed |
| 33946131 | A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions. | CPT Pharmacometrics Syst Pharmacol | 2021 | https://conductscience.org/library/papers/33946131 | PubMed |
| 33687157 | Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator. | CPT Pharmacometrics Syst Pharmacol | 2021 | https://conductscience.org/library/papers/33687157 | PubMed |
| 32543786 | Data Digitizing: Accurate and Precise Data Extraction for Quantitative Systems Pharmacology and Physiologically-Based Pharmacokinetic Modeling. | CPT Pharmacometrics Syst Pharmacol | 2020 | https://conductscience.org/library/papers/32543786 | PubMed |
| 32026490 | A Drug-Drug Interaction Study to Evaluate the Effect of TAS-303 on CYP3A Activity in the Small Intestine and Liver. | J Clin Pharmacol | 2020 | https://conductscience.org/library/papers/32026490 | PubMed |
| 30887238 | Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations. | AAPS J | 2019 | https://conductscience.org/library/papers/30887238 | PubMed |
| 30260092 | A Strategy to Refine the Phenotyping Approach and Its Implementation to Predict Drug Clearance: A Physiologically Based Pharmacokinetic Simulation Study. | CPT Pharmacometrics Syst Pharmacol | 2018 | https://conductscience.org/library/papers/30260092 | PubMed |
| 30194612 | A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4. | Clin Pharmacokinet | 2019 | https://conductscience.org/library/papers/30194612 | PubMed |
| 30171692 | CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans. | Br J Clin Pharmacol | 2018 | https://conductscience.org/library/papers/30171692 | PubMed |
| 30091221 | PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin. | CPT Pharmacometrics Syst Pharmacol | 2018 | https://conductscience.org/library/papers/30091221 | PubMed |
| 29686151 | Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29686151 | PubMed |
| 29574682 | Human hepatocytes and cytochrome P450-selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450s. | Br J Pharmacol | 2018 | https://conductscience.org/library/papers/29574682 | PubMed |
| 28910306 | A quantitative systems pharmacology approach, incorporating a novel liver model, for predicting pharmacokinetic drug-drug interactions. | PLoS One | 2017 | https://conductscience.org/library/papers/28910306 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CYP3A4 | 1576 | PubTator's text mining | https://conductscience.org/library/genes/1576 |
Source NCBI Gene
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| ABIRATERONE ACETATE | CHEMBL271227 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL271227 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/16580903
GET https://conductscience.org/api/papers/v1/16580903/cited_by?page=2